Triptan (5-HT₁B/1D agonist)
Eletriptan
Brand names: Relpax
Adult dose
Dose: 40mg at onset; may repeat after 2h if recurrence; max 80mg/24h
Route: Oral
Frequency: PRN; max 2 doses per attack
Clinical pearls
- NICE NG150: triptan first-line for acute migraine; eletriptan strongest receptor binding among oral triptans
- BASH / ABN migraine guidance
- Limit use ≤10 days/month to avoid medication overuse headache
Contraindications
- IHD
- Uncontrolled hypertension
- Stroke / TIA
- Hemiplegic / basilar migraine
- Concurrent or recent MAOI/ergotamine
- Severe hepatic impairment
- Concurrent strong CYP3A4 inhibitors (avoid)
Side effects
- Tightness/pressure (chest, throat)
- Dizziness
- Drowsiness
- Tingling
- Medication overuse headache
Interactions
- MAOIs
- Ergotamine (separate by 24h)
- Strong CYP3A4 inhibitors (avoid: clarithromycin, ritonavir, ketoconazole)
- Other serotonergics
Monitoring
- Headache diary
- CV risk factors
- MOH risk
Reference: BNF; NICE NG150; BASH; ABN migraine guidance; https://bnf.nice.org.uk/drugs/eletriptan/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Acute Stroke Management · NICE NG128 / RCP 2023
- TIA Assessment (ABCD2) · NICE NG128 / NICE CG68
- Bacterial Meningitis (Adults) · NICE CG102 / BIA 2016
- Parkinson's Disease Management · NICE NG71 2017